Bausch + Lomb

Yahoo Finance • last month

Bausch + Lomb (BLCO) Study Shows XIIDRA Eye Drops Improve Comfort For Contact Lens Wearers

Bausch + Lomb recently announced positive results from a study on XIIDRA, enhancing its position in treating dry eye disease in contact lens wearers. This news, alongside the U.S. launch of ASANA gas permeable lenses and improved Q2 earnin... Full story

Yahoo Finance • 2 months ago

Bausch + Lomb (BLCO) Stock Is Up, What You Need To Know

What Happened? Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 3.1% in the afternoon session after comments from Federal Reserve Chair Jerome Powell raised investor hopes for future interest rate cuts. The move came as U.S. sto... Full story

Yahoo Finance • 2 months ago

Icahn representations resign Bausch + Lomb board after agreement termination

(Reuters) -Contact lens maker Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire investor Carl Icahn and some of his affiliates. The agree... Full story

Yahoo Finance • 2 months ago

Bausch Health rises after $300M worth insider purchase

[Bausch Health US headquarters in Bridgewater, NJ, USA.] JHVEPhoto/iStock Editorial via Getty Images Bausch Health (NYSE:BHC [https://seekingalpha.com/symbol/BHC]) shares added ~4% on Friday after John Paulson, a board member of the Canad... Full story

Yahoo Finance • 2 months ago

Howard Marks Reduces Stake in Garrett Motion Inc, Impacting Portfolio by -1.4%

Insightful Moves in the Second Quarter of 2025 Howard Marks (Trades, Portfolio) recently submitted the 13F filing for the second quarter of 2025, providing insights into his investment moves during this period. As the Chairman of Oaktree... Full story

Yahoo Finance • 2 months ago

Bausch + Lomb’s SWOT analysis: ophthalmology leader faces spin-off uncertainty

Bausch + Lomb Corporation (NYSE:BLCO, TSX:BLCO), a prominent player in the healthcare sector specializing in ophthalmology, has been navigating a complex landscape of market opportunities and corporate challenges. With a market capitalizat... Full story

Yahoo Finance • 2 months ago

Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know

What Happened? A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer Price Index (CPI) report,... Full story

Yahoo Finance • 2 months ago

Bausch Lomb (BLCO) Q2 Revenue Rises 5%

Key Points Revenue (GAAP) rose 5% year over year to $1.28 billion, surpassing expectations by $18 million. Adjusted EPS (non-GAAP) came in at $0.07, above the $0.06 consensus but down sharply from last year's $0.13. Net loss narrowed to $... Full story

Yahoo Finance • 2 months ago

Bausch + Lomb raises 2025 revenue guidance to $5.15B as dry eye and contact lens growth accelerate

Earnings Call Insights: Bausch + Lomb (BLCO) Q2 2025 MANAGEMENT VIEW * CEO Brenton L. Saunders reported "our constant currency revenue growth speaks to the breadth and depth of our portfolio and is driven by a mix of hero products and... Full story

Yahoo Finance • 2 months ago

Stock Index Futures Muted as Investors Await U.S. GDP Data and Fed Rate Decision, Microsoft and Meta Earnings on Tap

Trader at NYSE by Orhan Akkurt via Shutterstock September S&P 500 E-Mini futures (ESU25) are up +0.04%, andSeptember Nasdaq 100 E-Mini futures (NQU25) are up +0.10% this morning, pointing to a cautious open on Wall Street as investors awa... Full story

Yahoo Finance • 2 months ago

Bausch + Lomb Announces Publication Of Phase 3 Results On LUMIFY Preservative Free

(RTTNews) - Bausch + Lomb Corporation (BLCO) Tuesday said results from a Phase 3 study showed that LUMIFY Preservative Free is non inferior to LUMIFY redness reliever eye drops for reducing redness in the eyes. In the study, participants... Full story

Yahoo Finance • 3 months ago

Bausch & Lomb amends CEO contract and performance stock unit terms

Bausch & Lomb Corp. (NYSE:BLCO, TSX:BLCO) announced changes to the employment agreement of Chief Executive Officer Brenton L. Saunders, according to a press release statement based on a filing with the Securities and Exchange Commission.... Full story

Yahoo Finance • 3 months ago

Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity

MarketNewsUpdatesNews Commentary NEW YORK, July 22, 2025 /CNW/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030... Full story

Yahoo Finance • 3 months ago

Ophthalmic Implants Market: Focused Insights (2025-2030) Featuring Alcon, Carl Zeiss, Bausch + Lomb, Johnson & Johnson and 20 Other Industry Leaders

Company Logo North America leads with over 34% market share, while APAC shows a robust growth of 9.03%. Major players like Alcon, Carl Zeiss, and Johnson & Johnson drive innovation in advanced ocular devices and eye health solutions. Oph... Full story

Yahoo Finance • 3 months ago

Bausch + Lomb Will Release Second-Quarter 2025 Financial Results on July 30 and Hold Investor Day on Nov. 13

VAUGHAN, Ontario, June 30, 2025--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on W... Full story

Yahoo Finance • 4 months ago

BAUSCH & LOMB ALERT: Bragar Eagel & Squire, P.C. is Investigating Bausch + Lomb Corporation on Behalf of Bausch & Lomb Stockholders and Encourages Investors to Contact the Firm

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Bausch + Lomb Corporation (“Bausch & Lomb” or the “Company”) (NYSE:BL... Full story

Yahoo Finance • 4 months ago

Barclays Cut Bausch & Lomb Target to $16, Keeping Rating Neutral in Early June

Barclays lowered its price target on Bausch & Lomb (NYSE: BLCO) from $19 to $16 on June 6, maintaining an Equalweight rating. The revision reflects a more cautious outlook on the company’s near-term financial performance. The firm trimmed... Full story

Yahoo Finance • 4 months ago

Bausch + Lomb announces pricing of upsized senior secured notes offering

* Bausch + Lomb (TSX:BLCO:CA [https://seekingalpha.com/symbol/BLCO:CA]) on Wednesday said its subsidiaries, Bausch+Lomb Netherlands B.V. and Bausch & Lomb, have priced the offering of €675M aggregate principal amount of senior secured fl... Full story

Yahoo Finance • 4 months ago

Bausch + Lomb announces €600m senior secured notes offering

AMSTERDAM/NEW YORK - Bausch + Lomb Netherlands B.V. and Bausch & Lomb Incorporated announced Wednesday they are offering €600 million in senior secured notes with a 5.5-year floating rate, according to a stabilization notice. J.P. Morgan... Full story

Yahoo Finance • 4 months ago

Bausch + Lomb's SWOT analysis: ophthalmology leader faces headwinds in stock outlook

Bausch + Lomb Corp. (NYSE:BLCO, TSX:BLCO), a prominent player in the healthcare sector specializing in eye health products, has been navigating a complex market landscape. According to InvestingPro data, the company has demonstrated strong... Full story